首页|期刊导航|中草药（英文版）|Cardiometabolic reprogramming drives right ventricular dysfunction in pulmonary arterial hypertension:Novel mechanisms and therapeutic implications

Cardiometabolic reprogramming drives right ventricular dysfunction in pulmonary arterial hypertension:Novel mechanisms and therapeutic implications

Saihu Liu Mari Okazaki Yanling Wu

中草药（英文版）2026，Vol.18Issue(3)：494-498,5.

中草药（英文版）2026，Vol.18Issue(3)：494-498,5.DOI:10.1016/j.chmed.2026.05.004

Cardiometabolic reprogramming drives right ventricular dysfunction in pulmonary arterial hypertension:Novel mechanisms and therapeutic implications

Saihu Liu ¹Mari Okazaki ²Yanling Wu¹

作者信息

1. Key Laboratory for Traditional Chinese Korean Medicine Research(State Ethnic Affairs),Key Laboratory of Natural Medicines of the Changbai Mountain(Ministry of Education),College of Pharmacy,Yanbian University,Yanji 133002,China
2. Laboratory of Pharmacology,Faculty of Pharmaceutical Sciences,Josai University,Saitama 350-0295,Japan
折叠

摘要

关键词

cardiometabolic reprogramming/mitochondrial dysfunction/pulmonary arterial hypertension/right ventricular dysfunction/single-cell multi-omics technology

Key words

cardiometabolic reprogramming/mitochondrial dysfunction/pulmonary arterial hypertension/right ventricular dysfunction/single-cell multi-omics technology

引用本文复制引用

Saihu Liu,Mari Okazaki,Yanling Wu..Cardiometabolic reprogramming drives right ventricular dysfunction in pulmonary arterial hypertension:Novel mechanisms and therapeutic implications[J].中草药（英文版）,2026,18(3):494-498,5.

基金项目

The authors express their gratitude to Department of Science and Technology of Jilin Province(No.20250205012GH),National Natural Science Foundation of China(Nos.82560813,81973555). （No.20250205012GH）

中草药（英文版）

ISSN：1674-6384

访问量0

下载量0

段落导航